Brief: Kura Oncology And Mirati Therapeutics Enter Into Clinical Collaboration
02/11/2023 12:17
Nov 2 (Reuters) - Kura Oncology Inc KURA.O :
* KURA ONCOLOGY AND MIRATI THERAPEUTICS ENTER INTO CLINICAL
COLLABORATION AND SUPPLY AGREEMENT TO EVALUATE KO-2806 AND
ADAGRASIB IN KRASᴳ¹²ᶜ-MUTATED NSCLC
* KURA ONCOLOGY INC - UNDER TERMS OF AGREEMENT, KURA WILL
SPONSOR
PHASE 1 STUDY OF KO-2806 AND ADAGRASIB IN PATIENTS WITH
KRAS(G12C)-MUTATED NSCLC
* KURA ONCOLOGY INC - MIRATI WILL SUPPLY KURA WITH ADAGRASIB
FOR
STUDY
Source text for Eikon: ID:nGNX5hgWf5
Further company coverage: KURA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mirati Therapeutics
See all newsBrief: European Commission Approves KRAZATI As A Targeted Treatment For Non-Small Cell Lung Cancer
US FDA turns down Amgen lung cancer drug Lumakras for full approval (updated)
US FDA turns down Amgen lung cancer drug Lumakras for full approval
Brief: Mirati Stockholders Voted 'For' Proposal To Adopt Deal Between Co, Bristol-Myers Squibb
Mirati's lung cancer drug gets EU's regulatory backing (updated)